Recursion Pharmaceuticals, Inc.
RXRX
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.9B
$3.63
▲ +5.52%
P/E
-3.49
Mkt Cap
$1.9B
52-Wk Range
$2.77–$7.18
52-Week Range
$2.77 - $7.18
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 21.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary AI-powered drug discovery platform
- Advanced computational biology technologies
- Diverse and innovative clinical pipeline
- Strategic pharmaceutical partnerships
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
Expanding AI capabilities in drug development
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+9.3% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying RXRX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 5, 2026
Reported EPS of -$0.25 vs -$0.24 consensus (-4.2% surprise). Revenue of $7.3M vs $11.0M expected (-33.4%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-4.2%
Revenue trend · last 8Q
—
-58%
+9%
+33%
-80%
+688%
-56%
-60%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$26.1M
$4.5M
$14.7M
$19.1M
$5.2M
$35.5M
$6.5M
$7.7M
Margins · last 8Q
Gross
-49.8%
Profit
-1708.0%
Wall Street consensus
3 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
—
Latest: Morgan Stanley · $5.50 · May 14, 2026
vs Industry
How RXRX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related